Programmed Death Ligand-1 Antagonists [MoA] - N0000193337

Name: Table of NDC products with programmed death ligand-1 antagonists
Creator: U.S. Food & Drug Administration
License: https://creativecommons.org/licenses/by-nc-sa/4.0/

Pharmacologic Class Information

Pharmacologic Code	N0000193337
Pharmacologic Name	Programmed Death Ligand-1 Antagonists
Pharmacologic Uses	programmed death ligand-1 (PD-L1) blocking antibody
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with Programmed Death Ligand-1 Antagonists

The table contains 3 products whose active ingredient are classified under the same pharmacologic class Programmed Death Ligand-1 Antagonists [MoA].

NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
0310-4500	Imfinzi	Non-Proprietary Name: Durvalumab	Injection, Solution	Intravenous	Astrazeneca Pharmaceuticals Lp	ACTIVE
0310-4611	Imfinzi	Non-Proprietary Name: Durvalumab	Injection, Solution	Intravenous	Astrazeneca Pharmaceuticals Lp	ACTIVE
44087-3535	Bavencio	Non-Proprietary Name: Avelumab	Injection, Solution, Concentrate	Intravenous	Emd Serono, Inc.	ACTIVE